droxidopa + carbidopa

Droxidopa + carbidopa is a theoretical or off-label drug combination that pairs two agents commonly used in the management of neurogenic orthostatic hypotension and Parkinson's disease. Droxidopa is a synthetic amino acid precursor of norepinephrine that increases blood pressure by being converted to norepinephrine via aromatic L-amino acid decarboxylase after crossing the blood-brain barrier[4][8]. It is primarily indicated to treat neurogenic orthostatic hypotension associated with conditions such as Parkinson's disease and multiple system atrophy[1][5]. Carbidopa is a peripheral dOPA-decarboxylase inhibitor that prevents the conversion of levodOPA or other precursors like droxidOPA to dopamine/norepinephrine outside the central nervous system; thus it can increase central availability of these neurotransmitters when co-administered[3]. While there are no fixed-dose combinations marketed specifically as "droxidopa + carbidopa," both drugs may be used together in clinical practice—especially in patients with Parkinson’s disease who require both symptomatic management of motor symptoms and treatment of autonomic dysfunction.

Brand names

Northera (for droxidopa)Lodosyn (for carbidopa)Sinemet (carbidopa/levodopa, not this combination but relevant for context)Rytary (carbidopa/levodopa, not this combination but relevant for context)Crexont (carbidopa/levodopa, not this combination but relevant for context)Sinemet CR (carbidopa/levodopa, not this combination but relevant for context)Duopa (carbidopa/levodopa, not this combination but relevant for context)